

1. [Two Indian generics makers end battle to copy drugs amid patent debate](#) – Reuters

BDR Pharma and Lee Pharma, had been seeking so-called compulsory licenses that override patents and allow generics firms in India to launch cheap copies of medicines manufactured by big Western drugmakers.

But now the two mid-sized generics players say their efforts have been thwarted by Prime Minister Narendra Modi's target to boost foreign investment in India and the resulting emphasis on protecting intellectual property, which is getting in the way of the

government's promise to provide cheap drugs for the poor. PM Modi has led a campaign to boost investment and manufacturing to speed up growth and create jobs, and is also reviewing the country's patent rules. A new intellectual property policy is due out soon.

1. [Two Indian generics makers end battle to copy drugs amid patent debate](#) – Reuters
2. [Medical Council of India should implement HC verdict: DMA](#) – Business Standard
3. ['Govt to crackdown on doctors-pharma firms' nexus'](#) – Hindustan Times
4. [Hefty bills preventing the sick from seeking medical help](#) – Hindu Business Line
5. [The Biosimilar Jigsaw](#) – Business Today
6. [A Bitter Pill](#) – Business Today
7. [MAKING PMS MANDATORY](#) – Pharmabiz
8. [CDSCO issues circular to pharma industry for assessing views on switch over to veg capsules from gelatin based capsules](#) – Pharmabiz
9. [Eli Lilly bets on diabetes, oncology, lines up new drugs](#) – Financial Express
10. [Tech Puts Healthcare Cos on Cloud MS](#) – Economic Times
11. [Changes in IPR policy could deter Make in India efforts: Assocham](#) – Hindu Business Line
12. [Column | DIPP's IPR consultation: Trying to fix what is not broken](#) – Financial Express

2. [Medical Council of India should implement HC verdict: DMA](#) – Business Standard

Delhi Medical Association (DMA), which is an association of registered medical practitioners of Allopathic System of Medicine affiliated to the Indian Medical Association (IMA), had filed a petition before the HC saying practitioners of 'Bharatiya Chikitsa' in the capital were prescribing allopathic drugs, jeopardizing the health of residents of the city. They also highlighted that it is important to check the business run by quacks in various areas of Delhi and urged MCI and DMC to conduct frequent raids and file police complaints against the defaulters.

Similar article appeared in [New Indian Express](#)

3. ['Govt to crackdown on doctors-pharma firms' nexus'](#) – Hindustan Times

To regulate the system, the ministry is coming up with new codes of conduct for pharmaceutical companies where firms will be directed not to give any gifts or payment to doctors. The ministry will make the order mandatory and it will be issued in a month or so. The pharmaceutical companies will not give any freebies to doctors. The binding will be on doctors as well. BPPI will launch media plan to create awareness among people and doctors about the generic medicines.

4. [Hefty bills preventing the sick from seeking medical help](#) – Hindu Business Line

The Health of India survey conducted between January and June 2014 indicated that in the rural areas, 57 per cent who do not see a doctor cited financial constraints, while in cities 68 per cent belonged to this category. A clear indication of rising costs can be seen here. The survey also

revealed that the entire process of seeking medical attention entails enormous out-of-pocket expenditure; hospitalisation accounts for just a fraction of total healthcare costs in India (28 per cent in rural and 32 per cent in urban).

5. [The Biosimilar Jigsaw](#) – Business Today
Even before the biosimilar guidelines were issued, India had started approving launch of biosimilar drugs in the country and, currently, there are around eight products in the market - in fact, India has more biosimilars than any other developed country. A lot would now depend on the feedback the drug controller receives within the 30-day window that will shape the final policy. Indian players will be hoping the guidelines are not tinkered with, but given the number of MNCs operating in India, it may not be the case.
6. [A Bitter Pill](#) – Business Today
From the industry point of view, the decision of banning FDCs was abrupt, as none of the procedural stakeholder consultations that normally precede such announcements, happened in this case. The apex medicine regulator - the office of the Drugs Controller General of India (DGCI), has an entirely opposite view. The article explains how.
7. [MAKING PMS MANDATORY](#) – Pharmabiz
The objective of the ministry now, is to make pharmacovigilance reporting mandatory on pharma companies in a bid to have detailed ADR data from the industry. In fact, the health ministry directed all the pharmaceutical companies last year to follow the practice of submission of Periodic Safety Update Reports (PSURs) of drugs on a regular basis but there has been no response from the industry so far.
8. [CDSCO issues circular to pharma industry for assessing views on switch over to veg capsules from gelatin based capsules](#) – Pharmabiz
CDSCO has circulated a notice to the pharmaceutical companies inviting suggestions on the proposal to replace gelatin capsules with vegetable capsules in the pharmaceutical industry. The move to consider vegetable capsules over gelatin based version is a welcome step. But the pharma industry will require some time to change over to this packaging option.
9. [Eli Lilly bets on diabetes, oncology, lines up new drugs](#) – Financial Express
Managing Director of global pharma major Eli Lilly said the company will widen its therapeutic drug portfolio to include pain management and others while it would launch one diabetic and cancer drug in India.

Similar article appeared in [Business Standard](#), [Hindu Business Line](#)
10. [Tech Puts Healthcare Cos on Cloud MS](#) – Economic Times
As companies explore how to counter the escalating costs of delivering services, many are turning to the cloud. The cloud computing market has started to witness unprecedented interest from the healthcare services sector, as the industry seeks to counter escalating costs of delivering services amid growing demand for better experience from patients. Considering this change, Microsoft is helping healthcare providers in India adapt IT tools like cloud, analytics and machine learning.
11. [Changes in IPR policy could deter Make in India efforts: Assocham](#) – Hindu Business Line
With the deadline approaching to submit opinions for a discussion paper, rolled out by the Department of Industrial Policy and Promotion (DIPP) on Standard Essential Patents (SEP), Assocham has joined the fray by writing an official letter to DIPP saying any changes to current policy would severely impact 'Make-in-India' efforts.
12. [Column | DIPP's IPR consultation: Trying to fix what is not broken](#) – Financial Express
There is an urgent need to strengthen, and not weaken, IPR policies for realising Make-in-India goals. In fact, we need to concurrently encourage and support Design-in-India, without which we would not have high quality manufacturing on a sustainable basis.